

VistaGen Therapeutics, Inc.  
 Form 4  
 December 24, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 DOTSON JERROLD DUANE

(Last) (First) (Middle)

C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO, CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

VistaGen Therapeutics, Inc. [VSTA]

3. Date of Earliest Transaction (Month/Day/Year)

12/20/2013

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 \_\_\_\_ Officer (give title below) \_\_\_\_\_ Other (specify below)

CFO AND SECRETARY

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |                                   |
|                                 |                                      |  |                                | Code  | V   | Amount   |                                   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative | 2. Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if | 4. Transaction | 5. Number of Derivative | 6. Date Exercisable and Expiration Date | 7. Title and Amount Underlying Security |
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|---|---|
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|---|---|

Edgar Filing: VistaGen Therapeutics, Inc. - Form 4

| Security<br>(Instr. 3)               | or Exercise<br>Price of<br>Derivative<br>Security | any<br>(Month/Day/Year) | Code<br>(Instr. 8) | Securities Acquired<br>(A) or Disposed of<br>(D)<br>(Instr. 3, 4, and 5) | (Month/Day/Year) |        | (Instr. 3 and 4)    |                    |                 |                                     |
|--------------------------------------|---|-------------------------|--------------------|--|------------------|--------|---------------------|--------------------|-----------------|-------------------------------------|
|                                      |   |                         | Code               | V  | (A)              | (D)    | Date<br>Exercisable | Expiration<br>Date | Title           | Amount<br>or<br>Number<br>of Shares |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.75   | 12/20/2013              | D                  |  | 13,541           |        | 10/30/2012          | 10/30/2022         | Common<br>Stock | 13,541                              |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.5  | 12/20/2013              | A                  |  | 13,541           |        | 10/30/2012          | 10/30/2022         | Common<br>Stock | 13,541                              |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.75   | 12/20/2013              | D                  |  |                  | 86,459 | <u>(2)</u>          | 10/30/2022         | Common<br>Stock | 86,459                              |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.5  | 12/20/2013              | A                  |  | 86,459           |        | <u>(2)</u>          | 10/30/2022         | Common<br>Stock | 86,459                              |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.75   | 12/20/2013              | D                  |  |                  | 6,249  | 10/30/2012          | 10/30/2022         | Common<br>Stock | 6,249                               |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.5  | 12/20/2013              | A                  |  | 6,249            |        | 10/30/2012          | 10/30/2022         | Common<br>Stock | 6,249                               |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.75   | 12/20/2013              | D                  |  |                  | 6,251  | <u>(2)</u>          | 10/30/2022         | Common<br>Stock | 6,251                               |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 0.5  | 12/20/2013              | A                  |  | 6,251            |        | <u>(2)</u>          | 10/30/2022         | Common<br>Stock | 6,251                               |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 2.1  | 12/20/2013              | D                  |  |                  | 1,000  | 01/17/2008          | 01/17/2018         | Common<br>Stock | 1,000                               |
| Stock<br>Option<br>(Right to         | \$ 0.5  | 12/20/2013              | A                  |  | 1,000            |        | 01/17/2008          | 01/17/2018         | Common<br>Stock | 1,000                               |

Buy)

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                      |       |
|---|---------------|-----------|----------------------|-------|
|   | Director      | 10% Owner | Officer              | Other |
| DOTSON JERROLD DUANE<br>C/O VISTAGEN THERAPEUTICS, INC.<br>343 ALLERTON AVENUE<br>SOUTH SAN FRANCISCO, CA 94080 |               |           | CFO AND<br>SECRETARY |       |

## Signatures

/s/ Jerrold D.  
Dotson

12/24/2013

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person agreed to cancellation of an option granted 10/30/2012 in exchange for a new option having a lower exercise price.
- (2) Option vests monthly over a period of two years commencing 10/30/2012.
- (3) The Reporting Person agreed to cancellation of an option granted 1/17/2008 in exchange for a new option having a lower exercise price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.